Cerebrospinal fluid neurofilament: The biomarker that will resuscitate the ?Spinal Tap?

Multiple Sclerosis

Volumn 16, Issue 3, 2010, Pages 285-286

  Giovannoni, Gavin ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; BETA INTERFERON; NEUROFILAMENT PROTEIN;

AXONAL INJURY; CEREBROSPINAL FLUID; CLINICAL TRIAL; DISEASE COURSE; DISEASE SEVERITY; HUMAN; MULTIPLE SCLEROSIS; NERVE REGENERATION; NEUROFILAMENT; NEUROLOGIC DISEASE; NEUROPROTECTION; NOTE; PROGNOSIS; PROTEIN BLOOD LEVEL; PROTEIN CEREBROSPINAL FLUID LEVEL; RELAPSE; REMISSION;

BIOLOGICAL MARKERS; EARLY DIAGNOSIS; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; NEUROFILAMENT PROTEINS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RISK ASSESSMENT; RISK FACTORS; SEVERITY OF ILLNESS INDEX; SPINAL PUNCTURE; TIME FACTORS; UP-REGULATION;

EID: 77949889957     PISSN: 13524585     EISSN: None     Source Type: Journal    
DOI: 10.1177/1352458510361358     Document Type: Note

References (11)

1. Petzold A. Neurofilament phosphoforms: surrogate markers for axonal injury, degeneration and loss. J Neurol Sci 2005 ; 233: 183-198.
2. Salzer J., Sundstrom P., Svenningsson A. Neurofilament light as a prognostic marker in multiple sclerosis. Mult Scler 2010 ; 16: 287-292.
3. Lycke JN, Karlsson JE, Andersen O., Rosengren LE Neurofilament protein in cerebrospinal fluid: a potential marker of activity in multiple sclerosis. J Neurol Neurosurg Psychiatry 1998 ; 64: 402-404.
4. Malmestrom C., Haghighi S., Rosengren L., Andersen O., Lycke J. Neurofilament light protein and glial fibrillary acidic protein as biological markers in MS. Neurology 2003 ; 61: 1720-1725.
5. Haghighi S., Andersen O., Oden A., Rosengren L. Cerebrospinal fluid markers in MS patients and their healthy siblings. Acta Neurol Scand 2004 ; 109: 97-99.
6. Petzold A., Eikelenboom MJ, Keir G., et al. Axonal damage accumulates in the progressive phase of multiple sclerosis: three year follow up study. J Neurol Neurosurg Psychiatry 2005 ; 76: 206-211.
7. Semra YK, Seidi OA, Sharief MK Heightened intrathecal release of axonal cytoskeletal proteins in multiple sclerosis is associated with progressive disease and clinical disability. J Neuroimmunol 2002 ; 122: 132-139.
8. Norgren N., Rosengren L., Stigbrand T. Elevated neurofilament levels in neurological diseases. Brain Res 2003 ; 987: 25-31.
9. Eikelenboom MJ, Petzold A., Lazeron RH, et al. Multiple sclerosis: Neurofilament light chain antibodies are correlated to cerebral atrophy. Neurology 2003 ; 60: 219-223.
10. Petzold A., Rejdak K., Plant GT Axonal degeneration and inflammation in acute optic neuritis. J Neurol Neurosurg Psychiatry 2004 ; 75: 1178-1180.
11. Petzold A., Brassat D., Mas P., et al. Treatment response in relation to inflammatory and axonal surrogate marker in multiple sclerosis. Mult Scler 2004 ; 10: 281-283.